External validation and comparison of IPI, R-IPI, and NCCN-IPI in diffuse large B-cell lymphoma patients treated with R-CHOP to predict 2-year progression-free survival

External validation and comparison of IPI, R-IPI, and NCCN-IPI in diffuse large B-cell lymphoma patients treated with R-CHOP to predict 2-year progression-free survival

Background Diffuse large B-cell lymphoma (DLBCL) is the most common aggressive lymphoma. The standard first-line therapy for DLBCL consists of rituximab cyclophosphamide doxorubicin vincristine and prednisone (R-CHOP). About 50–70% of patients may be cured by R-CHOP. There was no data on external va...

Full description

Bibliographic Details
Main Authors: Naree Warnnissorn, Nonglak Kanitsap, Pimjai Niparuck, Paisarn Boonsakan, Prapasri Kulalert, Wasithep Limvorapitak, Lantarima Bhoopat, Supawee Saengboon, Pichika Chantrathammachart, Teeraya Puavilai, Suporn Chuncharunee
Format: Article
Language:English
Published: Taylor & Francis Group 2022-12-01
Series:Hematology
Subjects:
Diffuse large B-cell lymphoma
R-CHOP
external validation
comparison
international prognostic index
revised-international prognostic index
Online Access:https://www.tandfonline.com/doi/10.1080/16078454.2022.2147916

Internet

https://www.tandfonline.com/doi/10.1080/16078454.2022.2147916

Similar Items